Search Result

Results for "

proton pump

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Proton Pump (76) Apoptosis (17) Autophagy (15) Bacterial (41) Cuproptosis (2) Drug Metabolite (7) Endogenous Metabolite (2) Fungal (2) Isotope-Labeled Compounds (15) Phospholipase (10) TOPK (4)
By Research Areas:	Cancer (53) Cardiovascular Disease (2) Endocrinology (13) Infection (19) Inflammation/Immunology (51) Metabolic Disease (19)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Proton Pump Na+/K+ ATPase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13662S

Lansoprazole-d4 AG-1749-d₄	Proton Pump Bacterial	Inflammation/Immunology Cancer
Lansoprazole-d₄ is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid[1].

HY-139557

Zastaprazan JP-1366	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) is a **proton pump** inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases .

HY-109079A

Abeprazan hydrochloride DWP14012 hydrochloride; Fexuprazan hydrochloride	Proton Pump	Metabolic Disease
Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-109079

Abeprazan DWP14012; Fexuprazan	Proton Pump	Metabolic Disease
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-B0656

Rabeprazole 3 Publications Verification LY307640	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656A

Rabeprazole sodium 3 Publications Verification LY307640 sodium	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656S

Rabeprazole-d4 LY307640-d₄	Proton Pump Apoptosis	Inflammation/Immunology Cancer
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-123754

AGN-201904	Proton Pump	Inflammation/Immunology
AGN-201904 is a **proton pump** inhibitor. AGN-201904 is an omeprazole prodrug that can delay aging and can be used to prevent and treat peptic ulcers .

HY-17507E

S-Pantoprazole sodium trihydrate	Proton Pump Bacterial	Infection
S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as **proton pump** inhibitor .

HY-B0656AS2

Rabeprazole-d4 potassium LY307640-d₄ potassium	Apoptosis Bacterial Proton Pump Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656R

Rabeprazole (Standard)	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (Standard) is the analytical standard of Rabeprazole. This product is intended for research and analytical applications. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-19223

Pumaprazole BY-841	Proton Pump	Inflammation/Immunology
Pumaprazole is a reversible **proton pump** antagonist.

HY-400540

Padoprazanum Padoprazan	Proton Pump	Inflammation/Immunology
Padoprazanum (Padoprazan) is a proton pump inhibitor .

HY-15295

Vonoprazan Fumarate 5 Publications Verification TAK-438	Proton Pump	Metabolic Disease Cancer
Vonoprazan Fumarate (TAK-438), a **proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀** of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-G0007

Omeprazole sulfone Omeprazole sulphone	Drug Metabolite	Infection Cancer
Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-100007A

Vonoprazan hydrochloride TAK-438 hydrochloride	Proton Pump Bacterial	Infection Endocrinology Cancer
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .

HY-100007

Vonoprazan 5 Publications Verification TAK-438 free base	Proton Pump Bacterial	Endocrinology Cancer
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-100007R

Vonoprazan (Standard) TAK-438 (Standard)	Proton Pump Bacterial	Endocrinology
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-105220

WY-47766 OST-766	Proton Pump	Inflammation/Immunology
WY-47766(OST-766) is aproton pumpinhibitor .

HY-101646

Saviprazole HOE-731	Proton Pump	Cardiovascular Disease
Saviprazole is a **Proton Pump** inhibitor. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .

HY-100560S

Abscisic acid-d6 (S)-(+)-Abscisic acid-d₆; ABA-d₆	Proton Pump	Metabolic Disease
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].

HY-17421A

Tenatoprazole sodium TU-199 sodium	Proton Pump	Cardiovascular Disease
Tenatoprazole sodium (TU-199 sodium) is a **proton pump inhibitor; inhibits hog gastric H ⁺/K ⁺-ATPase with an IC₅₀** of 6.2 μM.

HY-141776S

Omeprazole sulfide-d3 Ufiprazole-d₃	Drug Metabolite	Others
Omeprazole sulfide-d₃ is the deuterium labeled Omeprazole sulfide. Omeprazole metabolite Omeprazole sulfide (Ufiprazole) is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-121851

Revaprazan SB 641257	Proton Pump	Inflammation/Immunology
Revaprazan (SB 641257) is a reversible **proton pump** inhibitor with significant anti-inflammatory effects. Revaprazan can be used for chronic gastric inflammation research .

HY-G0007S

Omeprazole sulfone-d3 Omeprazole sulfone-d₃; Omeprazole sulphone-d₃	Isotope-Labeled Compounds Drug Metabolite	Infection Cancer
Omeprazole metabolite Omeprazole sulfone-d₃ is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-B0113S2

Omeprazole metabolite Omeprazole sulfone (methoxy-d3) Omeprazole sulfone (methoxy-d₃); Omeprazole sulphone (methoxy-d₃)	Isotope-Labeled Compounds Drug Metabolite	Infection Cancer
Omeprazole metabolite Omeprazole sulfone (methoxy-d₃) is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-109546

Omeprazole magnesium	Proton Pump	Metabolic Disease Cancer
Omeprazole magnesium is an orally active **proton pump** inhibitor (PPI) and can suppress gastric acid. Omeprazole magnesium can be used for acid reflux-related symptoms and frequent heartburn research .

HY-123662

AGN-201904Z	Others	Others
AGN-201904Z is a compound that inhibits gastric acid secretion and is a new type of proton pump inhibitor that can produce more significant and lasting acid suppression effects than esomeprazole.

HY-B0572

Zinc Pyrithione Maximum Cited Publications 7 Publications Verification	Cuproptosis Proton Pump Bacterial Fungal	Infection Metabolic Disease
Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump . Zinc Pyrithione is also a copper ionophore that delivers copper into cells and is a useful tool for studying cuproptosis .

HY-148051

Ilaprazole sulfone	Drug Metabolite	Inflammation/Immunology Cancer
Ilaprazole sulfone is the major metabolite of Ilaprazole (HY-101664), is predominantly catalysed by CYP3A4/5. Ilaprazole (IY-81149) is an orally active proton pump inhibitor .

HY-13662

Lansoprazole 2 Publications Verification AG-1749	Proton Pump Bacterial Phospholipase	Inflammation/Immunology Cancer
Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-13662A

Lansoprazole sodium AG-1749 sodium	Proton Pump Phospholipase Bacterial	Inflammation/Immunology
Lansoprazole sodium (AG 1749 sodium) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole sodium (AG 1749 sodium) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-17021B

Esomeprazole potassium salt (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021

Esomeprazole (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active **proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase** in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-101664

Ilaprazole IY-81149	Proton Pump TOPK	Inflammation/Immunology Cancer
Ilaprazole (IY-81149) is an orally active **proton pump inhibitor. Ilaprazole irreversibly inhibits H ⁺/K ⁺-ATPase in a dose-dependent manner with an IC₅₀** of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .

HY-118283

5-Hydroxylansoprazole 1 Publications Verification AG1908	Proton Pump	Metabolic Disease
5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric *proton-pump* inhibitor and is effective in the treatment of various peptic diseases .

HY-109023

Azeloprazole	Others	Others
Azeloprazole is a compound used to inhibit acid-related diseases. It is a proton pump inhibitor that inhibits H?,K?-ATPase in pig gastric vesicles. It can effectively inhibit gastric acid secretion in the dog's gastric fistula model. The effect is long-lasting and superior to esomeprazole.

HY-13662B

(R)-Lansoprazole 2 Publications Verification Dexlansoprazole	Proton Pump	Inflammation/Immunology Cancer
(R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-17021C

Esomeprazole hemistrontium (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active **proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase** in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .

HY-N7031

(±)-Vasicine (±)-Peganine	Proton Pump	Inflammation/Immunology
(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H ⁺-K ⁺-ATPase activity?in vitro?with an IC₅₀ of 73.47?μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and?cytoprotective?effect .

HY-N7031R

(±)-Vasicine (Standard)	Proton Pump	Inflammation/Immunology
(±)?-Vasicine (Standard) is the analytical standard of (±)?-Vasicine. This product is intended for research and analytical applications. (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC₅₀ of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .

HY-17021A

Esomeprazole magnesium salt (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-13662C

(S)-Lansoprazole Levolansoprazole	Proton Pump Phospholipase Bacterial	Inflammation/Immunology
(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-W003467

Rabeprazole Sulfide	Proton Pump Bacterial	Infection Inflammation/Immunology
Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a **proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H ⁺/K ⁺)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori**. Rabeprazole has the potential for various peptic diseases treatment .

HY-101664R

Ilaprazole (Standard)	Proton Pump TOPK	Inflammation/Immunology Cancer
Ilaprazole (Standard) is the analytical standard of Ilaprazole. This product is intended for research and analytical applications. Ilaprazole (IY-81149) is an orally active **proton pump inhibitor. Ilaprazole irreversibly inhibits H ⁺/K ⁺-ATPase in a dose-dependent manner with an IC₅₀** of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .

HY-17023S

Esomeprazole-d6 sodium (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium	Isotope-Labeled Compounds Proton Pump	Others
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0572R

Zinc Pyrithione (Standard)	Cuproptosis Proton Pump Bacterial Fungal	Infection Metabolic Disease
Zinc Pyrithione (Standard) is the analytical standard of Zinc Pyrithione. This product is intended for research and analytical applications. Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump . Zinc Pyrithione is also a copper ionophore that delivers copper into cells and is a useful tool for studying cuproptosis .

HY-W013186S

Lansoprazole sulfide-d4 AG-1777-d₄	Proton Pump Bacterial	Inflammation/Immunology
Lansoprazole sulfide-d₄ is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 µM intracellularly and 0.46 µM in broth[1].

HY-17021S

Esomeprazole-d3 sodium (S)-Omeprazole-d₃ sodium; (-)-Omeprazole-d₃ sodium	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17021S1

Esomeprazole-d3 (S)-Omeprazole-d₃; (-)-Omeprazole-d₃	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

Cat. No.	Product Name

HY-L011

Membrane Transporter/Ion Channel Compound Library

1,491 compounds

Most of molecules enter or leave cells mainly via membrane transport proteins, which play important roles in several cellular functions, including cell metabolism, ion homeostasis, signal transduction, the recognition process in the immune system, energy transduction, etc. There are three major types of transport proteins, ATP-powered pumps, channel proteins and transporters. Transport proteins such as channels and transporters play important roles in the maintenance of intracellular homeostasis, and mutations in these transport protein genes have been identified in the pathogenesis of a number of hereditary diseases. In the central nervous system, ion channels have been linked to, but not limited to, many diseases such asataxias, paralyses, epilepsies, and deafness. This indicates the roles of ion channels in the initiation and coordination of movement, sensory perception, and encoding and processing of information. Ion channels are a major class of drug targets in drug development.

MCE designs a unique collection of 1,491 smal-molecule modulators that can be used for the research of Ion Channel and Membrane Transporter or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7031

(±)-Vasicine (±)-Peganine	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Zygophyllaceae Peganum harmala Linn. Source classification Plants Inflammation/Immunology Disease Research Fields	Proton Pump
(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H ⁺-K ⁺-ATPase activity?in vitro?with an IC₅₀ of 73.47?μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and?cytoprotective?effect .

HY-100560

Abscisic acid 1 Publications Verification (S)-(+)-Abscisic acid; ABA	Structural Classification Classification of Application Fields Source classification Metabolic Disease Plants Endogenous metabolite Agricultural Research Microorganisms other families Animals Terpenoids Sesquiterpenes Abscisic acid Phytohormone Disease Research Fields	Endogenous Metabolite Proton Pump
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits **proton pump (H ⁺-ATPase**) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-N7031R

(±)-Vasicine (Standard)	Alkaloids Structural Classification Other Alkaloids Zygophyllaceae Peganum harmala Linn. Source classification Plants	Proton Pump
(±)?-Vasicine (Standard) is the analytical standard of (±)?-Vasicine. This product is intended for research and analytical applications. (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC₅₀ of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .

HY-100560R

Abscisic acid (Standard)	Structural Classification Microorganisms other families Animals Terpenoids Sesquiterpenes Source classification Plants Endogenous metabolite	Endogenous Metabolite Proton Pump
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P72099

	ATP6AP2 Protein, Human (His) APT6M8 9; APT6M8-9; ATP6AP2; ATP6IP2; ATP6M8-9; ATPase H+; -transporting lysosomal accessory protein 2; ATPase H+; -transporting lysosomal-interacting protein 2; ATPase H+ transporting lysosomal accessory protein 2; ATPase; H+ transporting; lysosomal vacuolar proton pump; membrane sector associated protein M8 9;	Human	E. coli
	The multifunctional ATP6AP2 protein serves as a cellular receptor for renin and prorenin, contributing to lysosomal V-ATPase assembly and endolysosomal acidification. It participates in renin-dependent reactions, activates ERK1/2, and may enhance the catalytic efficiency of renin in the renin-angiotensin system. ATP6AP2 Protein, Human (His) is the recombinant human-derived ATP6AP2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of ATP6AP2 Protein, Human (His) is 334 a.a., with molecular weight of ~40 kDa.

HY-P702861

	ATP6V0D1 Protein, Human (GST) V-type proton ATPase subunit d 1; V-ATPase subunit d 1; 32 kDa accessory protein; V-ATPase 40 kDa accessory protein; V-ATPase AC39 subunit (p39); Vacuolar proton pump subunit d 1	Human	E. coli
	ATP6V0D1 Protein, Human (GST) is the recombinant human-derived ATP6V0D1, expressed by E. coli , with N-GST labeled tag. The total length of ATP6V0D1 Protein, Human (GST) is 351 a.a.,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13662S

Lansoprazole-d4
Lansoprazole-d₄ is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid[1].

HY-B0656S

Rabeprazole-d4

Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-100560S

Abscisic acid-d6
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].

HY-141776S

Omeprazole sulfide-d3
Omeprazole sulfide-d₃ is the deuterium labeled Omeprazole sulfide. Omeprazole metabolite Omeprazole sulfide (Ufiprazole) is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-B0113S2

Omeprazole metabolite Omeprazole sulfone (methoxy-d3)
Omeprazole metabolite Omeprazole sulfone (methoxy-d₃) is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-W013186S

Lansoprazole sulfide-d4
Lansoprazole sulfide-d₄ is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 µM intracellularly and 0.46 µM in broth[1].

HY-B0656AS2

Rabeprazole-d4 potassium

Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-G0007S

Omeprazole sulfone-d3
Omeprazole metabolite Omeprazole sulfone-d₃ is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-17023S

Esomeprazole-d6 sodium
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S

Esomeprazole-d3 sodium
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17021S1

Esomeprazole-d3
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17021S2

Esomeprazole-d3 potassium
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active **proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase** in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0113S

Omeprazole-d₃ 1 Publications Verification
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-13662BS

(R)-Lansoprazole-d4
(R)-Lansoprazole-d₄ is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

HY-B0656AS

Rabeprazole-d4 sodium

Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-B0656AS1

Rabeprazole-d3 sodium

Rabeprazole-d₃ (sodium)mis the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-B0656S1

Rabeprazole-13C,d3

Rabeprazole-13C,d3 is a deuterated labeled Rabeprazole . Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17507S

Pantoprazole-d6

Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

HY-17507S1

Pantoprazole-d3

Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-N6948S

Linalyl acetate-d6

Linalyl acetate-d₆ is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S3

Omeprazole-13CD3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks